What is the Market's View on Indaptus Therapeutics Inc (INDP) Stock's Price and Volume Trends Monday?
Monday, March 27, 2023 03:28 PM | InvestorsObserver Analysts
Overall market sentiment has been high on Indaptus Therapeutics Inc (INDP) stock lately. INDP receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.
Indaptus Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on INDP!
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With INDP Stock Today?
Indaptus Therapeutics Inc (INDP) stock is lower by -5.41% while the S&P 500 has risen 0.52% as of 3:17 PM on Monday, Mar 27. INDP is down -$0.11 from the previous closing price of $1.94 on volume of 43,729 shares. Over the past year the S&P 500 is down -12.76% while INDP is down -55.34%. INDP lost -$1.73 per share in the over the last 12 months.
More About Indaptus Therapeutics Inc
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma in standard pre-clinical models.
Click Here to get the full Stock Report for Indaptus Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
